Evidence provided here demonstrates that the platinum resistance of CA125-negative cells is pharmacologically reversible with birinapant, and combination of this well-tolerated treatment with carboplatin standard therapy can significantly decrease tumour burden in subsets of HGSCs. The gene discussed is MUC16; the disease is neoplasm.